Cyclooxygenase-2 as a target for anticancer drug development
- 13 March 2006
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 59 (1) , 51-64
- https://doi.org/10.1016/j.critrevonc.2006.01.003
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Tumour-educated macrophages promote tumour progression and metastasisNature Reviews Cancer, 2004
- Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II studyInternational Journal of Cancer, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Cyclooxygenase‐2 expression in endometrial carcinomaCancer, 2002
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Identification of FAP Locus Genes from Chromosome 5q21Science, 1991
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971